Abstract Details

Title Contribution of fluorodeoxyglucose positron emission tomography (FDG-PET) in myelitis: a multicentre cohort of 13 cases

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 182

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
PRESENTER	No disclosure on file
Gerry Rowse	No disclosure on file
	No disclosure on file
	No disclosure on file
Giovanni Castelnovo	No disclosure on file
	No disclosure on file
Clarisse Carra-Dalliere	No disclosure on file
Xavier Ayrignac	Xavier Ayrignac has nothing to disclose.
Nicolas Gaillard	No disclosure on file
	No disclosure on file
Dimitri Renard, MD (CHU Nimes, Hopital Caremeau)	No disclosure on file
	No disclosure on file
Eric Thouvenot, MD, PhD (CHU De Nimes - Hopital Caremeau)	Dr. Thouvenot has received personal compensation in the range of $0-$499 for serving as a Consultant for Biogen. Dr. Thouvenot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biologix FZCo.. Dr. Thouvenot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Thouvenot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Thouvenot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for HEALTHME. Dr. Thouvenot has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Thouvenot has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Thouvenot has received research support from Biogen. The institution of Dr. Thouvenot has received research support from Novartis. The institution of Dr. Thouvenot has received research support from Roche.
	No disclosure on file
	No disclosure on file
Pierre Labauge, MD	Dr. Labauge has nothing to disclose.